Paper · 42909555
DPP9 modulates RPA1 stability and temozolomide sensitivity through RFWD3 Nuclear localization in glioma.
Wang W and 5 others. Cell Oncol (Dordr), 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. DPP9 modulates RPA1 stability and temozolomide sensitivity through RFWD3 Nuclear localization in glioma. Papers, record 42909555. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42909555
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- DPP9 modulates RPA1 stability and temozolomide sensitivity through RFWD3 Nuclear localization in glioma.
- Journal
- Cell Oncol (Dordr)
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-02
Source PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Temozolomide | Major topic |
| Glioma | Major topic |
| Cell Nucleus | Major topic |
| Replication Protein A | Major topic |
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | Major topic |
| Brain Neoplasms | Major topic |
| Humans | |
| Animals | |
| Cell Line, Tumor | |
| Ubiquitination | |
| Drug Resistance, Neoplasm | |
| DNA Damage | |
| Protein Stability | |
| Mice, Nude | |
| Protein Transport | |
| Mice | |
| Antineoplastic Agents, Alkylating |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No. YJXYY202204 | the Research Hospital Program of the Jiangsu Provincial Health Commission | PubMed | ||
| No. YJXYY202204 | the Research Hospital Program of the Jiangsu Provincial Health Commission | PubMed | ||
| No. YJXYY202204 | the Research Hospital Program of the Jiangsu Provincial Health Commission | PubMed | ||
| No. YJXYY202204 | the Research Hospital Program of the Jiangsu Provincial Health Commission | PubMed | ||
| No. YJXYY202204 | the Research Hospital Program of the Jiangsu Provincial Health Commission | PubMed | ||
| No. YJXYY202204 | the Research Hospital Program of the Jiangsu Provincial Health Commission | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38,724,526 | Glioma. | Nat Rev Dis Primers | 2024 | https://conductscience.org/library/papers/38724526 | PubMed |
| 2 | 17,051,156 | Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. | Nature | 2006 | https://conductscience.org/library/papers/17051156 | PubMed |
| 3 | 38,760,442 | IDH inhibition in gliomas: from preclinical models to clinical trials. | Nat Rev Neurol | 2024 | https://conductscience.org/library/papers/38760442 | PubMed |
| 4 | 28,145,904 | Overcoming therapeutic resistance in glioblastoma: the way forward. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28145904 | PubMed |
| 5 | 34,171,339 | Genotoxic therapy and resistance mechanism in gliomas. | Pharmacol Ther | 2021 | https://conductscience.org/library/papers/34171339 | PubMed |
| 6 | 40,180,114 | ADAM12 promotes temozolomide resistance in glioblastoma by activating the TNF-α - NF-κB pathway. | Cancer Lett | 2025 | https://conductscience.org/library/papers/40180114 | PubMed |
| 7 | 40,108,111 | α-synuclein expression in glioblastoma restores tumor suppressor function and rescues temozolomide drug resistance. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40108111 | PubMed |
| 8 | 21,383,502 | Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. | J Clin Invest | 2011 | https://conductscience.org/library/papers/21383502 | PubMed |
| 9 | 40,645,185 | KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. | Cancer Cell | 2025 | https://conductscience.org/library/papers/40645185 | PubMed |
| 10 | 28,622,525 | ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. | Mol Cell | 2017 | https://conductscience.org/library/papers/28622525 | PubMed |
1 to 10 of 32
See all 32 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42909555
GET https://conductscience.org/api/papers/v1/42909555/references?page=2